Vaccines for Invasive Fungal Infections

Overview

Journal F1000 Med Rep

Specialty General Medicine

Date 2011 Aug 31

PMID 21876719

Citations 28

Authors

Brad Spellberg

Affiliations

Soon will be listed here.

Abstract

Morbidity and mortality from invasive fungal infections remain unacceptably high despite availability of new antifungal agents, underscoring the need for more effective preventative strategies. Due to our enhanced understanding of the host defense and pathogenetic mechanisms that lead to invasive fungal infections, it should be feasible to develop vaccines targeting these infections. A common immunological theme across many vaccine candidates for invasive fungal infections has been the need to activate a cell-based, pro-inflammatory, Th1 or Th17 immune response to improve phagocytic killing of the fungi. Since neutralization of virulence factor functions has not been required for many active vaccines to function, the antigenic repertoire available for testing should not be limited to virulence factors. With expansion of our fundamental understanding of the immunology of fungal infections, the biggest barrier to development of fungal vaccines is the lack of available capital to translate discoveries made at the bench into biological agents used at the bedside. Continued education on the importance and feasibility of vaccination for such infections, combined with continued development of vaccine antigens and adjuvants, is necessary.

Citing Articles

Antifungal immunity: advances in PRR recognition, adaptive responses, and immune-based therapies.

Zhou J, Lu X, He R, Du Y, Zeng B, Feng L Sci China Life Sci. 2025; .

PMID: 40055278 DOI: 10.1007/s11427-024-2835-y.

infections: aspartyl protease potential to improve outcome in susceptible hosts.

Vernel-Pauillac F, Laurent-Winter C, Fiette L, Janbon G, Aimanianda V, Dromer F mBio. 2024; 15(11):e0273324.

PMID: 39440979 PMC: 11559057. DOI: 10.1128/mbio.02733-24.

Immunoinformatic-guided designing and evaluating protein and mRNA-based vaccines against Cryptococcus neoformans for immunocompromised patients.

Elalouf A, Yaniv-Rosenfeld A J Genet Eng Biotechnol. 2023; 21(1):108.

PMID: 37882985 PMC: 10603020. DOI: 10.1186/s43141-023-00560-3.

Simultaneous Determination of Posaconazole and Hemp Seed Oil in Nanomicelles through RP-HPLC via a Quality-by-Design Approach.

Rathee A, Solanki P, Verma S, Vohora D, Javed Ansari M, Aodah A ACS Omega. 2023; 8(33):30057-30067.

PMID: 37636934 PMC: 10448652. DOI: 10.1021/acsomega.3c02097.

Invasive fungal infections.

Kwarteng Owusu S Afr J Thorac Crit Care Med. 2022; 28(3).

PMID: 36285011 PMC: 9549933. DOI: 10.7196/AJTCCM.2022.v28i3.264.

References

Spellberg B, Ibrahim A, Avenissian V, Filler S, Myers C, Fu Y . The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun. 2005; 73(9):6191-3. PMC: 1231102. DOI: 10.1128/IAI.73.9.6191-6193.2005. View

Bromuro C, Romano M, Chiani P, Berti F, Tontini M, Proietti D . Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine. 2010; 28(14):2615-23. DOI: 10.1016/j.vaccine.2010.01.012. View

Wuthrich M, Filutowicz H, Allen H, Deepe G, Klein B . V beta1+ J beta1.1+/V alpha2+ J alpha49+ CD4+ T cells mediate resistance against infection with Blastomyces dermatitidis. Infect Immun. 2006; 75(1):193-200. PMC: 1828383. DOI: 10.1128/IAI.01148-06. View

Leung T, Li C, Hung E, Chan P, Mo C, Wong R . Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. Eur J Haematol. 2004; 72(5):353-7. DOI: 10.1111/j.1600-0609.2004.00216.x. View

Luo G, Ibrahim A, Spellberg B, Nobile C, Mitchell A, Fu Y . Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis. 2010; 201(11):1718-28. PMC: 3933264. DOI: 10.1086/652407. View

Wilson L, Reyes C, Stolpman M, Speckman J, Allen K, Beney J . The direct cost and incidence of systemic fungal infections. Value Health. 2002; 5(1):26-34. DOI: 10.1046/j.1524-4733.2002.51108.x. View

Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown A, Bistoni F . A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine. 2009; 28(7):1717-25. DOI: 10.1016/j.vaccine.2009.12.021. View

Ito J, Lyons J . Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis. 2002; 186(6):869-71. DOI: 10.1086/342509. View

Spellberg B, Ibrahim A, Avanesian V, Fu Y, Myers C, Phan Q . Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis. 2006; 194(2):256-60. DOI: 10.1086/504691. View

10.

Masur H, Kaplan J, Holmes K . Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2003; 137(5 Pt 2):435-78. DOI: 10.7326/0003-4819-137-5_part_2-200209031-00002. View

11.

Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C . An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun. 2007; 75(11):5085-94. PMC: 2168274. DOI: 10.1128/IAI.00278-07. View

12.

Tedaldi E, Baker R, Moorman A, Wood K, Fuhrer J, McCabe R . Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004; 38(10):1478-84. DOI: 10.1086/420740. View

13.

Chu J, Feudtner C, Heydon K, Walsh T, Zaoutis T . Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis. 2006; 42(6):822-5. DOI: 10.1086/500405. View

14.

Wuthrich M, Filutowicz H, Warner T, Deepe Jr G, Klein B . Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med. 2003; 197(11):1405-16. PMC: 2193905. DOI: 10.1084/jem.20030109. View

15.

Shoham S, Huang C, Chen J, Golenbock D, Levitz S . Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001; 166(7):4620-6. DOI: 10.4049/jimmunol.166.7.4620. View

16.

Luong M, Lam J, Chen J, Levitz S . Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine. 2007; 25(22):4340-4. PMC: 2001175. DOI: 10.1016/j.vaccine.2007.03.027. View

17.

Stevens D, Clemons K, Liu M . Developing a vaccine against aspergillosis. Med Mycol. 2010; 49 Suppl 1:S170-6. DOI: 10.3109/13693786.2010.497775. View

18.

Dockrell D, Poland G, Steckelberg J, Wollan P, Strickland S, Pomeroy C . Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine. 1999; 17(22):2779-85. DOI: 10.1016/s0264-410x(99)00089-4. View

19.

Specht C, Nong S, Dan J, Lee C, Levitz S . Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis. 2007; 196(5):796-800. DOI: 10.1086/520536. View

20.

Lin L, Ibrahim A, Avanesian V, Edwards Jr J, Fu Y, Baquir B . Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant. Clin Vaccine Immunol. 2008; 15(3):582-4. PMC: 2268268. DOI: 10.1128/CVI.00427-07. View